Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia 1

Interventions

fludarabine phosphate 3Whole-Body Irradiation 3Melphalan 3Cyclophosphamide 3Azacitidine 3fludarabine 2Mycophenolic Acid 2Imatinib Mesylate 2venetoclax 1treosulfan 1tislelizumab 1thymoglobulin 1ruxolitinib 1pevonedistat 1peginterferon alfa-2a 1nilotinib 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Sirolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Maintenance 1Immune Checkpoint Inhibitors 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Decitabine 1Dasatinib 1Cord Blood Stem Cell Transplantation 1Clofarabine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Tyrosine Kinase Inhibitors × Myeloid × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡